Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Athens Medical C.S.A. (IATR.AT)
Athens, GR
Athens Medical C.S.A., together with its affiliated companies, operates and holds ownership of hospital facilities both within Greece and on an international scale. The organization delivers extensive diagnostic and treatment options for various cancers, such as those affecting the breast, gastrointestinal system, blood, liver and pancreas, lungs, prostate, skin, bladder, kidneys, and female reproductive organs. Additionally, it offers advanced robotic surgery, neurosurgical procedures, spinal operations, and therapies for cardiac ailments. Its services encompass a broad range of orthopedic specialties, addressing conditions of the foot and ankle, hand and wrist, hip, knee, shoulder, and spine, in addition to treating sports-related injuries. The company also provides care for chronic conditions including diabetes, endocrine disorders, heart failure, high blood pressure, pain management, respiratory system issues, stroke, and thyroid conditions. Furthermore, Athens Medical C.S.A. runs wellness and preventative health centers and performs cosmetic and reconstructive plastic surgery. The group is also involved in medical education, training, and practical service provision, alongside offering patient care guidance. It currently manages eight hospital units, which collectively feature 1,200 beds. Founded in 1984, Athens Medical C.S.A. is headquartered in Athens, Greece.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.28% | +1.41% | -5.53% | -4.01% | -4.52% | -9.34% | +3.16% | +22.95% | +4.97% | +171.15% | +79.50% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+2.2% Q4'25: +4.6% (vs Q4'23)
-
EPS growth Medical - Care Facilities: +19.2%-362.4% Q4'25: -22,466.7% (vs Q4'23)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%-6.7% Q4'25: -2.8% (vs Q4'23)
-
EBIT margin Medical - Care Facilities: +11.3%+3.0% Q4'25: -0.1% (vs Q4'23)
-
ROIC Medical - Care Facilities: +6.8%+3.3% Q4'25: -0.2% (vs Q4'23)
-
Share dilution Medical - Care Facilities: +0.0%+0.0% Q4'25: +0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×6.56× Q4'25: 4.42× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2010 actual |
Dec 2011 actual |
|---|---|---|
| Revenue |
233.37M
est: 245.52M (-5.0%)
|
219.00M
est: 221.23M (-1.0%)
|
| EBITDA |
7.37M
est: 33.31M (-77.9%)
|
9.79M
est: 30.02M (-67.4%)
|
| EBIT |
-5.04M
est: 18.54M (-127.2%)
|
31.17M
est: 16.71M (+86.5%)
|
| Net Income |
-13.38M
|
-19.09M
|
| SGA |
35.91M
est: 5.63M (+537.8%)
|
39.09M
est: 5.07M (+670.5%)
|
| EPS |
-0.15
|
-0.22
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-26 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-25 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-19 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-18 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-15 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Anagnostopoulou Theodora | Investor Relations Officer | — | — |
| Anna Xydia | Corporate Secretary | — | female |
| Christos G. Apostolopoulos | First Executive Vice President of the Board | — | male |
| Fanis Nezeritis | Head of Technical Department | — | male |
| Georgios Boutsioukos | Executive Director | — | male |
| Georgios V. Apostolopoulos | President of the Board | — | — |
| Georgios Zerdilas | Executive Director | — | male |
| Mpoytsioykos Georgios | Executive Director | — | male |
| Nikolaos Kavoulis | Chief Information Security Officer | — | male |
| Panagiotis Katsichtis | Chief Accountant | — | male |
| Petros D. Adamopoulos | Chief Financial Officer | — | male |
| Theodora Anagnostopoulou | Department Head of Investor Relations | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IATR.AT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
